Background
Human immunodeficiency virus (HIV) infection remains incurable due to latently infected cells resistant to anti-retroviral therapy (ART). One HIV cure strategy is to permanently silence the latent reservoir. The HIV Tat, trans-activator of transcription, protein promotes productive transcriptional elongation, enabling the rapid production of viral proteins and virions. Therefore, we sought to mutate the Tat gene to reduce Tat expression and prevent HIV re-activation in latent cells.
Methods
In this study, we used CRISPR/Cas9 delivered by lipid nanoparticles (LNPs) to target the viral Tat gene (Tat-CR LNPs). We first optimized a T cell specific LNP formulation for RNA delivery, and then delivered Cas9 mRNA and guide RNAs (gRNAs) against Tat to HIV infected cells. We compared Tat-CR LNPs to non-target CR LNPs in a range of HIV infection models, including HIV infected Jurkat cells, a latently infected T cell line, and HIV infected primary CD4+ T cells.
Results
We observed potent reduction of HIV expression in HIV infected Jurkat cells that received Tat-CR LNPs compared to non-target CR LNPs. A single dose of Tat-CR LNPs reduced the % of GFP+ Jurkat cells from 63% to 4.5% (****, p <. 0.0001). ICE analysis determined that 81% of the sampled sequences contained insertion or deletion mutations around the gRNA cut site (R2 = 94.0). We also delivered Tat-CR LNPs to an inducible Jurkat-derived latency model and showed that Tat-CR LNPs inhibited reactivation of proviruses that had been stimulated with latency reversal agents. 2D10 cells treated with Tat-CR LNPs were largely protected from latency reversal by AZD, prostratin, and SAHA compared to non-target CR LNP treated samples (****, p < 0.0001). Finally, we tested Tat-CR LNPs in primary CD4+ T cells and showed partial knockdown (~50%) of HIV expression. Statistical differences were determined by unpaired t test or two-way ANOVA using Prism GraphPad software, and p < 0.05 were considered significant.
Conclusions
We show that our Tat-CR LNPs effectively deliver CRISPR/Cas9 components to immortalized and primary T cells. Sequence analysis indicates that most of the population is edited after a single dose of Tat-CR LNPs. Further, our results validate that genetically editing the HIV Tat gene significantly reduces HIV expression in three infected T cell models, including primary cells. Overall, this study suggests that our Tat-CR LNPs can target infected T cells, attenuate Tat expression, and prevent HIV reactivation in vitro.